UID:
almahu_9948025773002882
Format:
1 online resource (247 p.)
ISBN:
1-281-05897-1
,
9786611058975
,
0-08-053881-9
Series Statement:
Handbook of immunopharmacology. Drugs
Content:
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds availab
Note:
Description based upon print version of record.
,
Front Cover; Phosphodiesterase Inhibitors; Copyright Page; Contents; Contributors; Series Preface; Preface; Chapter 1. Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular BiologicaI Methods; 1. Introduction; 2. The PDE Gene Family; 3. Molecular Cloning and Localization of the Mammalian PDEs; 4. Summary; 5. References; Chapter 2. Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods; 1. Introduction; 2. Analysis of PDE Isoenzyme Activities in Cells and Tissues; 3. Regulation of PDE Isoenzyme Activities; 4. Conclusions; 5. References
,
Chapter 3. Effects of Theophylline and Non-selective Xanthine Derivatives on PDE Isoenzymes and Cellular Function1. Introduction; 2. Inhibition of PDE; 3. Effects on Cell Function; 4. Summary and Directions for Future Research; 5. References; Chapter 4. Ca 2+/Calmodulin-dependent Cyclic Nucleotide Phosphodiesterase (PDE1); 1. Introduction; 2. Purification and Characterization; 3. Isoenzymes of CaM-PDE; 4. Activity in Cancer Cells; 5. Conclusions; 6. Acknowledgements; 7. References; Chapter 5. EHNA as an Inhibitor of PDE2: a Pharmacological and Biochemical Study in Cardiac Myocytes
,
1. Introduction2. Methods; 3. Results; 4. Discussion; 5. Acknowledgements; 6. References; Chapter 6. cGMP-Inhibited Phosphodiesterases (PDE3); 1. Introduction; 2. Purification and Characterization; 3. Molecular Cloning and Domain Organization; 4. Structure/Function Relationships; 5. Pharmacology and Potential Therapeutic Usage of PDE3 Inhibitors; 6. Therapeutic Usage of PDE3 Inhibitors; 7. Acknowledgements; 8. References; Chapter 7. Interaction of PDE4 Inhibitors with Enzymes and Cell Functions; 1. The PDE4 Isoenzyme Family; 2. Pharmacology of PDE4 Inhibitors
,
3. Adverse Effects of PDE4 Inhibitors4. PDE4 Alterations in Allergic Diseases; 5. Summary and Future Directions; 6. References; Chapter 8. Inhibition of Phosphodiesterase Isoenzymes and Cell Function by Selective PDE5 Inhibitors; 1. Introduction; 2. Scientific Rationale for PDE5 Inhibitors; 3. PDE5 Inhibition and Vasorelaxation; 4. Potential Therapeutic Applications of PDE5 Inhibitors; 5. Additional Indications for PDE5 Inhibitors; 6. Newer PDE5 Inhibitors; 7. Combination Inhibitors; 8. Summary; 9. Acknowledgement; 10. References
,
Chapter 9. Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE51. Introduction; 2. Strategy for the Design of PDE5 Inhibitors; 3. Synthesis of IBMX and cGMP Analogues as PDE Inhibitors; 4. Selectivity of the IBMX Analogues as PDE Inhibitors; 5. cGMP Analogues as PDE Inhibitors; 6. Smooth Muscle Relaxation by IBMX and cGMP Analogues; 7. Conclusions; 8. Acknowledgements; 9. References; Chapter 10. Enzymatic and Functional Aspects of Dual-selective PDE3/4 Inhibitors; 1. Introduction; 2. Dual Inhibitors of PDE3/4 for Asthma Therapy
,
3. Preclinical Pharmacology of PDE3/4 Inhibitors
,
English
Additional Edition:
ISBN 0-12-210720-9
Language:
English
Bookmarklink